Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses.
Crimean-Congo Haemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. There is no approved vaccine currently available against CCHF. The most promising candidate, which has previously been shown to confer protection in the small animal model, is a modified Vaccinia Ankara virus vector expressing the CCHF viral glycoprotein (MVA-GP). It has been shown that MVA-GP induces both humoral and cellular immunogenicity. In the present study, sera and T-lymphocytes were passively and adoptively transferred into recipient mice prior to challenge with CCHF virus. Results demonstrated that mediators from both arms of the immune system were required to demonstrate protective effects against lethal challenge.
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Stuart D
SD
Dowall
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Victoria A
VA
Graham
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Emma
E
Rayner
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Laura
L
Hunter
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Robert
R
Watson
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Irene
I
Taylor
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Antony
A
Rule
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Miles W
MW
Carroll
Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom.
Roger
R
Hewson
D000349:Africa / Q000453:epidemiology; D000818:Animals; D001208:Asia / Q000453:epidemiology; D002460:Cell Line; D005061:Europe, Eastern / Q000453:epidemiology; D006023:Glycoproteins / Q000276:immunology*; D003225:Hemorrhagic Fever Virus, Crimean-Congo / Q000276:immunology*; D006479:Hemorrhagic Fever, Crimean / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D051379:Mice; D008877:Middle East / Q000453:epidemiology; D014616:Vaccinia virus / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D006023:Glycoproteins; D014764:Viral Proteins; D014765:Viral Vaccines